Ernexa Therapeutics Inc. has successfully completed its second closing of a private placement, raising approximately $6.0 million in gross proceeds. The company issued an aggregate of 47,717,087 shares of common stock and 9,332,000 pre-funded warrants. This follows an initial closing where Ernexa sold 9,934,016 shares of common stock and 509,736 pre-funded warrants. In total, the private placement has resulted in gross proceeds of around $7.0 million, bolstering the company's stockholders' equity to over $2.5 million. This move is part of Ernexa's strategy to comply with Nasdaq's continued listing requirements. The net proceeds from the issuance are intended for general working capital purposes.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。